A Phase 2 interventional study of ARGX-113 and Placebo in Myasthenia Gravis, sponsored by argenx. Completed at 19 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-28.
Sponsored by argenx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 16th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 2, and was the 1st registered.
331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:
argenx · Sites in United States, Belgium, Germany and 5 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 65+
argenx · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18+
Clinique Neuro-Outaouais · Sites in Canada
Ages 18–80
By country, each count listing its studies:
efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 4
First in 2016; this study’s year is marked. 1 started in 2016.
This study's enrollment of 24 is below the median of 44 across 217 interventional studies indexed under Myasthenia Gravis.
Median enrollment 55 across the 20 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 8 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
18 studies in Myasthenia Gravis by argenx: 9 open now, 12 under way, 5 of them phase 3. Of 6 finished, 6 (100%) have results posted.
Among the 18 studies in Myasthenia Gravis by argenx, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 2, and was the 1st registered.
argenx’s Myasthenia Gravis studies by the year they started, since 2016.
7 of the studies testing efgartigimod alfa in Myasthenia Gravis that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06765161Phase 3Clinique Neuro-OutaouaisEfgartigimod in IVIG Dependent Myasthenia Gravis Patients | 2027-01-06 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT07231523Phase 3Shanghai Zhongshan HospitalEFG vs IVIG in TAMG | 2027-06-01 |
| NCT06392386Phase 3argenxA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | 2027-09 |
| NCT06221501Shanghai Zhongshan HospitalPerioperative Efgartigimod for Thymoma and Myasthenia Gravis | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among argenx’s 18 in Myasthenia Gravis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, multicenter Phase II study to evaluate the safety, efficacy, and pharmacokinetics of ARGX-113 for the treatment of autoimmune Myasthenia Gravis (MG) with generalized muscle weakness.
Myasthenia Gravis (MG) is an autoimmune disorder characterized in most cases by T cell and antibody responses to neuromuscular junction proteins such as skeletal muscle nicotinic acetylcholine receptor (AChR). Antibodies against epitopes of the AChR of the neuromuscular junction cause failure of neuromuscular transmission, resulting in the characteristic fatigue and weakness associated with this severe disorder.
The study will evaluate an innovative candidate in MG.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of MG with generalized muscle weakness meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II, III, or IVa, and likely not in need of a respirator for the duration of the study as judged by the Investigator.
The confirmation of the diagnosis should be documented and supported by:
Patients are required to be on a stable dose of their MG treatment prior to randomization. For patients receiving AZA, other NSIDs, , and/or cholinesterase inhibitors as concomitant medications the following conditions will apply:
Note: cholinesterase inhibitors must be held for at least 12 hours consistent with the revised manual for the QMG test as recommended by the Myasthenia Gravis Foundation of America Inc (MGFA), before the MGQoL15r, MG-ADL, QMG, and MGC assessments.
Exclusion Criteria:
At Screening, have laboratory abnormalities or as below:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive ARGX-113
Biological: ARGX-113
During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive placebo
Drug: Placebo
Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs)
TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of the treatment. A treatment emergent SAE was any untoward medical occurrence that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent or significant disability or incapacity; was a congenital abnormality or birth defect; or other medically significant events. All TEAEs observed were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 with descriptions of severity for each AE based on the following general guideline: Grade 1= mild; Grade 2 = moderate; Grade 3 = severe or medically significant but not immediately life-threatening; Grade 4 = life-threatening consequences; Grade 5 = death related to AE.
Time frame: Day 1 to Day 78
Mean Change From Baseline in Vital Signs: Blood Pressure
The patients' diastolic and systolic blood pressure were measured pre-dose on dosing days 1,8,15 and 22 and also during the follow up period. The mean change from baseline at each time point is presented. Baseline is defined as the last non-missing value before first dose of study medication.
Time frame: Baseline and Days 8,15, 22, 29, 36, 43, 50, 64 and 78
Mean Change From Baseline in Vital Signs: Heart Rate
The patients' heart rate was measured pre-dose on dosing days 1,8,15 and 22 and also during the follow up period. The mean change from baseline at each time point is presented. Baseline is defined as the last non-missing value before first dose of study medication.
Time frame: Baseline and Days 8,15, 22, 29, 36, 43, 50, 64 and 78
Mean Change From Baseline in Vital Signs: Temperature
The patients' temperature was measured pre-dose on dosing days 1,8,15 and 22 and also during the follow up period. The mean change from baseline at each time point is presented. Baseline is defined as the last non-missing value before first dose of study medication.
Time frame: Baseline and Days 8,15, 22, 29, 36, 43, 50, 64 and 78
Mean Change From Baseline in Vital Signs: Weight
The patients' weight as measured pre-dose on dosing days 1,8,15 and 22 and also during the follow up period. The mean change from baseline at each time point is presented. Baseline is defined as the last non-missing value before first dose of study medication.
Time frame: Baseline and Days 8,15, 22, 29, 36, 43, 50, 64 and 78
Number of Patients With Abnormal Clinically Relevant Findings in Electrocardiogram (ECG) Parameters
ECG parameters of heart rate, PR, QT, and QRS interval were read locally and performed pre-dose on dosing days 1,8,15 and 22 and on the last follow up visit on Day 78. Any patients recording abnormal clinically relevant findings during the study are presented.
Time frame: Day 1 to Day 78
Number of Patients With Abnormal Clinical Laboratory Findings Reported as TEAEs
Sampling for clinical laboratory tests including hematology, clinical chemistry, and urinalysiswas performed pre-dose on dosing Days 1, 8, 15 and 22 and throughout the follow up period. Patients fasted for at least 8 hours prior to this sampling. Abnormal laboratory values, or test results were not reported as TEAEs unless they were associated with clinical signs and symptoms that were considered clinically relevant, required therapy or led to treatment discontinuation. Patients reporting TEAEs in any of the laboratory parameters during the study are presented.
Time frame: Day 1 to Day 78
Mean Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score
The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. It evaluates the capacity to perform different activities of daily living such as talking, chewing, swallowing, breathing, brushing the teeth/combing the hair, or arising from the chair and it also assesses double vision and eyelid droop. The 8 items are rated from 0 to 3 and the total score could point from 0 to 24; with higher scores indicating more impairment. The mean change in MG-ADL score from baseline is presented for each timepoint with a clinically meaningful improvement defined as a drop of at least 2 points as compared with baseline.
Time frame: Baseline and Days 8,15, 22, 29, 36, 43, 50, 64 and 78
Mean Change From Baseline in QMG Score
The QMG quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG consists of 13 items that includes ocular, bulbar, and limb function. Out of the 13 items, 6 are timed tests of endurance measured in seconds. Each item has a possible score from 0-3. The score range is 0-39, where higher scores indicate more severe impairments. The mean change in QMG score from baseline is presented with a clinically meaningful improvement defined as a drop of at least 3 points as compared with baseline.
Time frame: Baseline and Days 8,15, 22, 29, 36, 43, 50, 64 and 78
Mean Change From Baseline in MGC Score
The MGC has 10 items combining physician examination and patient-reported outcomes. The 2 ocular items are derived from QMG. It has 3 items on muscle strength (deltoids, hip flexors, and neck flexors or extensors) and 4 items on bulbar function (swallowing, chewing, breathing, and speech functions), based on the clinical history. Each item is scored on an ordinal scale with 4 possible categories, but the items are weighted, whereby bulbar impairments weigh more than ocular ones. The impairments that were examined by the Investigator included ptosis or upward gaze, double vision, eye closure, neck flexion, shoulder abduction, and hip flexion. The patient-reported outcomes under MGC are talking, chewing, swallowing, and breathing. The maximum possible score is 50 (range from 0-50), with higher scores reflecting more severe impairments. The mean change in MGC score from baseline is presented.
Time frame: Baseline and Days 8,15, 22, 29, 36, 43, 50, 64 and 78
Mean Change From Baseline in MGQoL15r Score
The MGQoL15r is a quality of life scale or survey of patient's responses that addresses MG-specific psychological well-being and social functioning. It is a brief questionnaire that is completed by the patient and uses 3 response options to help inform the clinician about the patient's perception of the extent of and dissatisfaction with MG-related dysfunction. Each item is scored from 0 to 2 according to its frequency, with a maximum score of 30 (range 0-30) and higher scores reflecting more severe impairment. The mean change in MGQoL15r score from baseline is presented.
Time frame: Baseline and Days 8,15, 22, 29, 36, 43, 50, 64 and 78
Maximum Reduction From Baseline in MG-ADL Score
The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. It evaluates the capacity to perform different activities of daily living such as talking, chewing, swallowing, breathing, brushing the teeth/combing the hair, or arising from the chair and it also assesses double vision and eyelid droop. The 8 items are rated from 0 to 3 and the total score could point from 0 to 24; with higher scores indicating more impairment. The mean maximum reduction from baseline across all visit days for MG-ADL score is presented.
Time frame: Day 1 to Day 78
Maximum Reduction From Baseline in QMG Score
The QMG quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG consists of 13 items that included ocular, bulbar, and limb function. Out of the 13 items, 6 are timed tests of endurance measured in seconds. Each item has a possible score from 0-3. The total possible score is 39 (range 0-39), where higher scores indicates more severe impairments. The mean maximum reduction from baseline across all visit days for QMG score is presented.
Time frame: Day 1 to Day 78
Maximum Reduction From Baseline in MGC Score
The MGC has 10 items combining physician examination and patient-reported outcomes. The 2 ocular items are derived from QMG. It has 3 items on muscle strength (deltoids, hip flexors, and neck flexors or extensors) and 4 items on bulbar function (swallowing, chewing, breathing, and speech functions), based on the clinical history. Each item is scored on an ordinal scale with 4 possible categories, but the items are weighted, whereby bulbar impairments weigh more than ocular ones. The impairments that were examined by the Investigator included ptosis or upward gaze, double vision, eye closure, neck flexion, shoulder abduction, and hip flexion. The patient-reported outcomes under MGC are talking, chewing, swallowing, and breathing. The maximum possible score is 50 (range 0-50), with higher scores reflecting more severe impairments. The mean maximum reduction from baseline across all visit days for MCG score is presented.
Time frame: Day 1 to Day 78
Maximum Reduction From Baseline in MGQoL15r Score
The MGQoL15r is a quality of life scale or survey of patient's responses that addresses MG-specific psychological well-being and social functioning. It is a brief questionnaire that was completed by the patient and uses 3 response options to help inform the clinician about the patient's perception of the extent of and dissatisfaction with MG-related dysfunction. Each item is scored from 0 to 2 according to its frequency, with a maximum score of 30 (range 0-30) and higher scores reflecting more severe impairment. The mean maximum reduction from baseline across all visit days for MGQoL15r score is presented.
Time frame: Day 1 to Day 78
Pharmacokinetic (PK) Parameters - Plasma Concentrations of ARGX-113
The appropriate PK parameters were calculated after single (Day 1) and multiple administrations (Days 8,15 and 22) of ARGX-113. The mean maximum observed plasma concentration (Cmax) and plasma concentration observed pre-dose (Ctrough) is presented.
Time frame: Days 1, 8, 15 and 22
PK Parameters - Median Time of Occurrence of Cmax (Tmax) of ARGX-113
The appropriate PK parameters were calculated after single (Day 1) and multiple administrations (Days 8, 15 and 22) of ARGX-113. The median tmax is presented.
Time frame: Days 1, 8 15 and 22.
PK Parameters - Apparent Terminal Half-life (t1/2 Lambda z) of ARGX-113
The t1/2 lambda z was calculated at Day 22.
Time frame: Day 22
PK Parameters - Accumulation Ratio (Rac) of ARGX-113
The Rac was calculated as Day 22 Cmax/Day 1 Cmax.
Time frame: Days 1 and 22.
Mean Percent Change From Baseline in Immunoglobulins (IgGs)
The pharmacodynamic (PD) biomarkers that were measured included the following IgGs: Total IgG and IgG isotypes; IgG1, IgG2, IgG3, IgG4. PD samples were collected pre-dose on dosing days and the mean percent change from baseline at the end of treatment (Day 22) and at the last follow up visit (Day 78) are presented.
Time frame: Baseline, Days 22 and 78
Mean Percent Change From Baseline in Anti-Acetylcholine Receptor (AChR) Antibodies
Analysis of the PD biomarkers included anti-AChR binding antibodies. PD samples were collected pre-dose on dosing days and the mean percent change from baseline at the end of treatment (Day 22) and at the last follow up visit (Day 78) are presented.
Time frame: Baseline, Days 22 and 78
Number of Patients With an Anti-drug Antibodies (ADA) Response
Blood samples to assess ADA were collected pre-dose on dosing days and throughout the follow up period. The overall number of patients with pre-dose and post-dose ADA titers are presented.
Time frame: Baseline up to Day 78
From 30 December 2016, 15 study centers in 8 countries (Belgium, Canada, Italy, the Netherlands, Poland, Spain, Sweden, and United States) consented at least 1 patient with myasthenia gravis (MG) who had generalized muscle weakness. The last patient last visit was 20 October 2017.
| Milestone | ARGX-113 | Placebo |
|---|---|---|
| Started | 12 | 12 |
| Completed | 11 | 12 |
| Not completed | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of the treatment. A treatment emergent SAE was any untoward medical occurrence that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent or significant disability or incapacity; was a congenital abnormality or birth defect; or other medically significant events. All TEAEs observed were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 with descriptions of severity for each AE based on the following general guideline: Grade 1= mild; Grade 2 = moderate; Grade 3 = severe or medically significant but not immediately life-threatening; Grade 4 = life-threatening consequences; Grade 5 = death related to AE.
| Participants | ARGX-113 | Placebo |
|---|---|---|
| At least 1 TEAE | 10 | 10 |
| At least 1 treatment-related TEAE | 8 | 3 |
| At least 1 treatment emergent SAE | 0 | 0 |
| Withdrawn from treatment with at least 1 TEAE | 0 | 0 |
| Discontinued study due to at least 1 TEAE | 0 | 0 |
| NCI-CTCAE severity Grade ≥3 | 0 | 0 |
| Number of Deaths | 0 | 0 |
The patients' diastolic and systolic blood pressure were measured pre-dose on dosing days 1,8,15 and 22 and also during the follow up period. The mean change from baseline at each time point is presented. Baseline is defined as the last non-missing value before first dose of study medication.
| millimeters mercury | ARGX-113 | Placebo |
|---|---|---|
| Systolic- Day 8 | 3.8 ± 9.12 | 6.3 ± 10.52 |
| Systolic- Day 15 | 4.5 ± 15.62 | 2.7 ± 10.97 |
| Systolic- Day 22 | 2.7 ± 9.30 | 3.0 ± 13.03 |
| Systolic- Day 29 | 8.2 ± 10.70 | 1.2 ± 9.06 |
| Systolic- Day 36 | 8.5 ± 12.93 | 3.2 ± 5.41 |
| Systolic- Day 43 | 5.4 ± 12.47 | 4.6 ± 8.27 |
| Systolic- Day 50 | 10.6 ± 9.78 | 6.6 ± 12.58 |
| Systolic- Day 64 | 4.3 ± 10.41 | 0.1 ± 14.84 |
| Systolic- Day 78 | 2.5 ± 10.82 | 6.8 ± 10.33 |
| Diastolic- Day 8 | -0.8 ± 7.48 | -0.3 ± 10.55 |
| Diastolic- Day 15 | 1.5 ± 9.58 | -0.8 ± 9.34 |
| Diastolic- Day 22 | -0.3 ± 6.01 | -2.3 ± 10.52 |
| Diastolic- Day 29 | 4.0 ± 8.95 | -4.4 ± 11.89 |
| Diastolic- Day 36 | 3.6 ± 11.73 | -0.3 ± 6.80 |
| Diastolic- Day 43 | 2.9 ± 6.95 | -5.1 ± 10.09 |
| Diastolic- Day 50 | 4.7 ± 7.38 | -0.5 ± 16.39 |
| Diastolic- Day 64 | 3.1 ± 4.77 | -4.7 ± 8.96 |
| Diastolic- Day 78 | 1.7 ± 7.28 | -3.5 ± 10.41 |
The patients' heart rate was measured pre-dose on dosing days 1,8,15 and 22 and also during the follow up period. The mean change from baseline at each time point is presented. Baseline is defined as the last non-missing value before first dose of study medication.
| beats/minute | ARGX-113 | Placebo |
|---|---|---|
| Day 8 | -2.7 ± 11.80 | 1.8 ± 11.66 |
| Day 15 | -4.1 ± 9.05 | 2.5 ± 12.40 |
| Day 22 | -0.8 ± 10.70 | -1.1 ± 12.15 |
| Day 29 | -2.4 ± 13.49 | 0.1 ± 9.75 |
| Day 36 | 1.1 ± 14.08 | 3.1 ± 11.87 |
| Day 43 | 0.2 ± 10.79 | 3.1 ± 15.49 |
| Day 50 | 0.5 ± 19.82 | 2.1 ± 12.98 |
| Day 64 | -4.0 ± 19.22 | 0.6 ± 8.71 |
| Day 78 | -3.1 ± 10.78 | -2.0 ± 15.12 |
The patients' temperature was measured pre-dose on dosing days 1,8,15 and 22 and also during the follow up period. The mean change from baseline at each time point is presented. Baseline is defined as the last non-missing value before first dose of study medication.
| degrees Centigrade | ARGX-113 | Placebo |
|---|---|---|
| Day 8 | 0.18 ± 0.493 | 0.15 ± 0.511 |
| Day 15 | 0.09 ± 0.535 | 0.16 ± 0.382 |
| Day 22 | 0.05 ± 0.613 | 0.27 ± 0.429 |
| Day 29 | -0.03 ± 0.459 | 0.11 ± 0.291 |
| Day 36 | -0.13 ± 0.620 | 0.09 ± 0.334 |
| Day 43 | -0.04 ± 0.563 | 0.08 ± 0.299 |
| Day 50 | -0.03 ± 0.341 | 0.10 ± 0.422 |
| Day 64 | 0.21 ± 0.593 | 0.17 ± 0.306 |
| Day 78 | 0.11 ± 0.552 | 0.18 ± 0.282 |
The patients' weight as measured pre-dose on dosing days 1,8,15 and 22 and also during the follow up period. The mean change from baseline at each time point is presented. Baseline is defined as the last non-missing value before first dose of study medication.
| kg | ARGX-113 | Placebo |
|---|---|---|
| Day 8 | 0.18 ± 0.443 | -0.02 ± 1.359 |
| Day 15 | 0.60 ± 0.768 | 0.31 ± 1.528 |
| Day 22 | 0.54 ± 0.672 | 0.01 ± 1.672 |
| Day 29 | 0.41 ± 0.729 | -0.04 ± 1.826 |
| Day 36 | 0.76 ± 0.840 | -0.02 ± 1.770 |
| Day 43 | 0.91 ± 2.093 | 0.31 ± 2.593 |
| Day 50 | 0.48 ± 1.156 | 0.44 ± 1.996 |
| Day 64 | 0.26 ± 1.052 | -0.27 ± 2.703 |
| Day 78 | 0.23 ± 1.238 | -0.60 ± 3.122 |
ECG parameters of heart rate, PR, QT, and QRS interval were read locally and performed pre-dose on dosing days 1,8,15 and 22 and on the last follow up visit on Day 78. Any patients recording abnormal clinically relevant findings during the study are presented.
| Participants | ARGX-113 | Placebo |
|---|---|---|
| Number of Patients With Abnormal Clinically Relevant Findings in Electrocardiogram (ECG) Parameters | 0 | 0 |
Sampling for clinical laboratory tests including hematology, clinical chemistry, and urinalysiswas performed pre-dose on dosing Days 1, 8, 15 and 22 and throughout the follow up period. Patients fasted for at least 8 hours prior to this sampling. Abnormal laboratory values, or test results were not reported as TEAEs unless they were associated with clinical signs and symptoms that were considered clinically relevant, required therapy or led to treatment discontinuation. Patients reporting TEAEs in any of the laboratory parameters during the study are presented.
| Participants | ARGX-113 | Placebo |
|---|---|---|
| B-lymphocyte count decreased | 2 | 0 |
| T-lymphocyte count decreased | 1 | 0 |
| Lymphocyte count decreased | 2 | 0 |
| Monocyte count decreased | 2 | 0 |
| Neutrophil count inceased | 2 | 0 |
| Blood thyroid stimulating hormone increased | 1 | 0 |
The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. It evaluates the capacity to perform different activities of daily living such as talking, chewing, swallowing, breathing, brushing the teeth/combing the hair, or arising from the chair and it also assesses double vision and eyelid droop. The 8 items are rated from 0 to 3 and the total score could point from 0 to 24; with higher scores indicating more impairment. The mean change in MG-ADL score from baseline is presented for each timepoint with a clinically meaningful improvement defined as a drop of at least 2 points as compared with baseline.
| score on a scale | ARGX-113 | Placebo |
|---|---|---|
| Day 8 | -1.9 ± 2.75 | -0.7 ± 1.56 |
| Day 15 | -2.8 ± 2.70 | -2.2 ± 2.08 |
| Day 22 | -3.5 ± 2.84 | -2.5 ± 2.50 |
| Day 29 | -4.1 ± 2.64 | -2.3 ± 2.72 |
| Day 36 | -4.2 ± 3.30 | -2.1 ± 2.43 |
| Day 43 | -3.8 ± 2.72 | -2.4 ± 2.69 |
| Day 50 | -4.4 ± 3.53 | -2.9 ± 2.96 |
| Day 64 | -3.4 ± 3.27 | -1.8 ± 3.55 |
| Day 78 | -3.5 ± 3.50 | -1.8 ± 4.22 |
The QMG quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG consists of 13 items that includes ocular, bulbar, and limb function. Out of the 13 items, 6 are timed tests of endurance measured in seconds. Each item has a possible score from 0-3. The score range is 0-39, where higher scores indicate more severe impairments. The mean change in QMG score from baseline is presented with a clinically meaningful improvement defined as a drop of at least 3 points as compared with baseline.
| score on a scale | ARGX-113 | Placebo |
|---|---|---|
| Day 8 | -2.8 ± 3.13 | 0.0 ± 2.22 |
| Day 15 | -4.0 ± 4.29 | -1.8 ± 3.08 |
| Day 22 | -4.0 ± 4.55 | -1.8 ± 3.91 |
| Day 29 | -4.9 ± 4.94 | -1.4 ± 3.72 |
| Day 36 | -5.7 ± 5.97 | -1.9 ± 3.37 |
| Day 43 | -4.6 ± 5.73 | -2.1 ± 4.55 |
| Day 50 | -5.5 ± 5.84 | -2.1 ± 3.95 |
| Day 64 | -4.5 ± 6.42 | -1.8 ± 4.59 |
| Day 78 | -4.8 ± 7.67 | -2.1 ± 5.07 |
The MGC has 10 items combining physician examination and patient-reported outcomes. The 2 ocular items are derived from QMG. It has 3 items on muscle strength (deltoids, hip flexors, and neck flexors or extensors) and 4 items on bulbar function (swallowing, chewing, breathing, and speech functions), based on the clinical history. Each item is scored on an ordinal scale with 4 possible categories, but the items are weighted, whereby bulbar impairments weigh more than ocular ones. The impairments that were examined by the Investigator included ptosis or upward gaze, double vision, eye closure, neck flexion, shoulder abduction, and hip flexion. The patient-reported outcomes under MGC are talking, chewing, swallowing, and breathing. The maximum possible score is 50 (range from 0-50), with higher scores reflecting more severe impairments. The mean change in MGC score from baseline is presented.
| score on a scale | ARGX-113 | Placebo |
|---|---|---|
| Day 8 | -4.3 ± 5.87 | -1.3 ± 2.77 |
| Day 15 | -5.8 ± 6.45 | -4.4 ± 4.56 |
| Day 22 | -7.8 ± 6.92 | -4.0 ± 3.86 |
| Day 29 | -8.7 ± 7.36 | -4.1 ± 5.22 |
| Day 36 | -9.0 ± 8.73 | -4.1 ± 5.58 |
| Day 43 | -8.6 ± 8.54 | -3.5 ± 5.97 |
| Day 50 | -9.4 ± 7.92 | -4.2 ± 5.51 |
| Day 64 | -7.2 ± 8.65 | -3.8 ± 6.84 |
| Day 78 | -7.1 ± 9.71 | -3.8 ± 6.83 |
The MGQoL15r is a quality of life scale or survey of patient's responses that addresses MG-specific psychological well-being and social functioning. It is a brief questionnaire that is completed by the patient and uses 3 response options to help inform the clinician about the patient's perception of the extent of and dissatisfaction with MG-related dysfunction. Each item is scored from 0 to 2 according to its frequency, with a maximum score of 30 (range 0-30) and higher scores reflecting more severe impairment. The mean change in MGQoL15r score from baseline is presented.
| score on a scale | ARGX-113 | Placebo |
|---|---|---|
| Day 8 | -2.0 ± 5.77 | -0.8 ± 1.86 |
| Day 15 | -3.7 ± 4.42 | -1.0 ± 2.76 |
| Day 22 | -4.3 ± 4.77 | -1.5 ± 3.17 |
| Day 29 | -4.7 ± 5.44 | -1.5 ± 2.91 |
| Day 36 | -6.0 ± 5.78 | -2.1 ± 3.58 |
| Day 43 | -5.3 ± 5.59 | -1.4 ± 3.70 |
| Day 50 | -4.4 ± 4.13 | -1.8 ± 3.71 |
| Day 64 | -3.7 ± 5.10 | -1.3 ± 3.68 |
| Day 78 | -2.7 ± 5.44 | -1.5 ± 3.61 |
The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. It evaluates the capacity to perform different activities of daily living such as talking, chewing, swallowing, breathing, brushing the teeth/combing the hair, or arising from the chair and it also assesses double vision and eyelid droop. The 8 items are rated from 0 to 3 and the total score could point from 0 to 24; with higher scores indicating more impairment. The mean maximum reduction from baseline across all visit days for MG-ADL score is presented.
| score on a scale | ARGX-113 | Placebo |
|---|---|---|
| Maximum Reduction From Baseline in MG-ADL Score | -5.1 ± 3.32 | -3.7 ± 2.93 |
The QMG quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG consists of 13 items that included ocular, bulbar, and limb function. Out of the 13 items, 6 are timed tests of endurance measured in seconds. Each item has a possible score from 0-3. The total possible score is 39 (range 0-39), where higher scores indicates more severe impairments. The mean maximum reduction from baseline across all visit days for QMG score is presented.
| score on a scale | ARGX-113 | Placebo |
|---|---|---|
| Maximum Reduction From Baseline in QMG Score | -7.3 ± 6.08 | -4.3 ± 4.16 |
The MGC has 10 items combining physician examination and patient-reported outcomes. The 2 ocular items are derived from QMG. It has 3 items on muscle strength (deltoids, hip flexors, and neck flexors or extensors) and 4 items on bulbar function (swallowing, chewing, breathing, and speech functions), based on the clinical history. Each item is scored on an ordinal scale with 4 possible categories, but the items are weighted, whereby bulbar impairments weigh more than ocular ones. The impairments that were examined by the Investigator included ptosis or upward gaze, double vision, eye closure, neck flexion, shoulder abduction, and hip flexion. The patient-reported outcomes under MGC are talking, chewing, swallowing, and breathing. The maximum possible score is 50 (range 0-50), with higher scores reflecting more severe impairments. The mean maximum reduction from baseline across all visit days for MCG score is presented.
| score on a scale | ARGX-113 | Placebo |
|---|---|---|
| Maximum Reduction From Baseline in MGC Score | -11.5 ± 7.61 | -7.7 ± 4.40 |
The MGQoL15r is a quality of life scale or survey of patient's responses that addresses MG-specific psychological well-being and social functioning. It is a brief questionnaire that was completed by the patient and uses 3 response options to help inform the clinician about the patient's perception of the extent of and dissatisfaction with MG-related dysfunction. Each item is scored from 0 to 2 according to its frequency, with a maximum score of 30 (range 0-30) and higher scores reflecting more severe impairment. The mean maximum reduction from baseline across all visit days for MGQoL15r score is presented.
| score on a scale | ARGX-113 | Placebo |
|---|---|---|
| Maximum Reduction From Baseline in MGQoL15r Score | -7.2 ± 5.42 | -3.0 ± 3.16 |
The appropriate PK parameters were calculated after single (Day 1) and multiple administrations (Days 8,15 and 22) of ARGX-113. The mean maximum observed plasma concentration (Cmax) and plasma concentration observed pre-dose (Ctrough) is presented.
| nanograms/milliliter (ng/mL) | ARGX-113 |
|---|---|
| Cmax - Day 1 | 179063.7 ± 31.9 |
| Cmax - Day 8 | 173960.4 ± 19.5 |
| Cmax - Day 15 | 153257.2 ± 22.1 |
| Cmax - Day 22 | 162655.6 ± 26.1 |
| Ctrough - Day 1 | 7266.2 ± 43.5 |
| Ctrough - Day 8 | 9894.8 ± 54.7 |
| Ctrough - Day 15 | 10045.5 ± 56.7 |
| Ctrough - Day 22 | 10944.6 ± 71.1 |
The appropriate PK parameters were calculated after single (Day 1) and multiple administrations (Days 8, 15 and 22) of ARGX-113. The median tmax is presented.
| hours | ARGX-113 |
|---|---|
| Day 1 | 2.44 (2.08 to 2.58) |
| Day 8 | 2.50 (2.08 to 2.50) |
| Day 15 | 2.50 (2.07 to 2.50) |
| Day 22 | 2.46 (2.08 to 2.67) |
The t1/2 lambda z was calculated at Day 22.
| hours | ARGX-113 |
|---|---|
| PK Parameters - Apparent Terminal Half-life (t1/2 Lambda z) of ARGX-113 | 116.08 ± 15.8 |
The Rac was calculated as Day 22 Cmax/Day 1 Cmax.
| ratio | ARGX-113 |
|---|---|
| PK Parameters - Accumulation Ratio (Rac) of ARGX-113 | 0.9360 ± 25.7 |
The pharmacodynamic (PD) biomarkers that were measured included the following IgGs: Total IgG and IgG isotypes; IgG1, IgG2, IgG3, IgG4. PD samples were collected pre-dose on dosing days and the mean percent change from baseline at the end of treatment (Day 22) and at the last follow up visit (Day 78) are presented.
| percentage change | ARGX-113 | Placebo |
|---|---|---|
| Total IgG - Day 22 | -70.0 ± 10.96 | -2.8 ± 15.34 |
| Total IgG - Day 78 | -20.4 ± 24.96 | 6.4 ± 27.49 |
| IgG1 - Day 22 | -65.5 ± 8.56 | -2.1 ± 9.29 |
| IgG1 - Day 78 | -16.0 ± 18.17 | -1.1 ± 19.01 |
| IgG2 - Day 22 | -61.0 ± 6.73 | -4.4 ± 6.99 |
| IgG2 - Day 78 | -34.9 ± 16.02 | -5.3 ± 17.63 |
| IgG3 - Day 22 | -65.25 ± 10.045 | 0.57 ± 9.566 |
| IgG3 - Day 78 | -5.19 ± 18.422 | 2.52 ± 15.341 |
| IgG4 - Day 22 | -49.48 ± 10.278 | 0.79 ± 6.592 |
| IgG4 - Day 78 | 4.16 ± 25.513 | 1.57 ± 16.730 |
Analysis of the PD biomarkers included anti-AChR binding antibodies. PD samples were collected pre-dose on dosing days and the mean percent change from baseline at the end of treatment (Day 22) and at the last follow up visit (Day 78) are presented.
| percentage change | ARGX-113 | Placebo |
|---|---|---|
| Day 22 | -52.2686 ± 26.32992 | -0.3236 ± 8.50886 |
| Day 78 | -1.3361 ± 34.33867 | -7.8881 ± 33.43325 |
Blood samples to assess ADA were collected pre-dose on dosing days and throughout the follow up period. The overall number of patients with pre-dose and post-dose ADA titers are presented.
| participants | ARGX-113 | Placebo |
|---|---|---|
| Patients with pre-dose ADA titers | 4 | 2 |
| Patients with post-dose ADA titers | 4 | 3 |
Collected over Day 1 to Day 78.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARGX-113 | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Placebo | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Event | ARGX-113 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 4/12 | 3/12 |
| ToothacheGastrointestinal disorders | 0/12 | 2/12 |
| Tooth abscessInfections and infestations | 0/12 | 2/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 2/12 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/12 | 0/12 |
| B-lymphocyte count decreasedInvestigations | 2/12 | 0/12 |
| Lymphocyte count decreasedInvestigations | 2/12 | 0/12 |
| Monocyte count decreasedInvestigations | 2/12 | 0/12 |
| Neutrophil count increasedInvestigations | 2/12 | 0/12 |
| PruritusSkin and subcutaneous tissue disorders | 1/12 | 2/12 |
Baseline characteristics are summarized for the randomized population which included patients who had been allocated to a randomized treatment group, regardless of whether they received the planned treatment or not.
| Age, Categorical(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 10 | 18 |
| >=65 years | 4 | 2 | 6 |
| Age, Continuous(years) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| Mean | 55.3 ± 13.60 | 43.5 ± 19.28 | 49.4 ± 17.39 |
| Sex: Female, Male(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| Female | 7 | 8 | 15 |
| Male | 5 | 4 | 9 |
| Ethnicity (NIH/OMB)(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 12 | 23 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 11 | 11 | 22 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Weight(kg) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| Mean | 74.08 ± 15.477 | 75.21 ± 14.343 | 74.64 ± 14.604 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Oct 2017, 9 months.
Results were first posted in Jan 2021, 3 years 2 months after primary completion. A results delay was requested in Oct 2018.
Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efgartigimod alfa